In the NewsSeptember 18, 2025Common Bloodstream and Respiratory RDTs to Optimize Therapy ManagementSeptember 12, 2025Making the Most of the Growing Array of Rapid Diagnostic TestsAugust 14, 2025The Top 25 Biotech and Life Sciences Companies of 2025July 20, 2025For infectious disease, plasma microbial cf-DNA testingJuly 19, 2025The BioHub - S2 Ep56 - Alec Ford & Stacy Solorio - KariusJune 3, 2025An Infectious Enthusiasm for AILoad morePress ReleasesApril 29, 2025Karius Launches Karius Focus™ | BAL: A Comprehensive and Timely Solution for Diagnosis and Management of Suspected Infectious Pneumonia and Other Lung Infections Among Immunocompromised PatientsAugust 8, 2024Karius Secures BARDA Contract to Expand Agnostic Detection of PathogensMay 16, 2024Karius Test® Receives FDA Breakthrough Device Designation to Aid in the Diagnosis of Infectious DiseaseMay 2, 2024Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance CrisisOctober 10, 2023Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood CancerAugust 10, 2023Karius Inc. Adds Dr. Norman Sharpless, Former National Cancer Institute Head, and Elizabeth O’Farrell, Eli Lilly Veteran, to its Board of Directors